Clinical Trials Using Gemcitabine Hydrochloride

Clinical trials are research studies that involve people. The clinical trials on this list are studying Gemcitabine Hydrochloride. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 90

  • Durvalumab in Combination with Chemotherapy in Treating Patients with Advanced Solid Tumors, (DURVA+ study)

    This phase II trial studies the side effects of durvalumab when given together with chemotherapy in treating patients with solid tumors that have spread to others places in the body (advanced). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride, capecitabine, carboplatin, paclitaxel, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with durvalumab may improve how immune cells respond and attack tumor cells.
    Location: National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland

  • Nivolumab, Cabiralizumab, and Gemcitabine Combination Therapy for the Treatment of Metastatic Pancreatic Cancer, Gem CaN Study

    This phase II trial studies how well nivolumab, cabiralizumab, and gemcitabine work for the treatment of pancreatic cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies such as nivolumab may help the body’s immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with cabiralizumab may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy such as gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab, cabiralizumab, and gemcitabine may work better in prolonging disease control in patients with pancreatic cancer compared to chemotherapy alone.
    Location: 3 locations

  • Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients with Locally Advanced or Metastatic Kidney Cancer

    This phase II trial studies how well ixazomib, gemcitabine, and doxorubicin work in treating patients with kidney cancer that has spread to other places in the body (locally advanced or metastatic). Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ixazomib, gemcitabine, and doxorubicin may work better in treating patients with kidney cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Testing the Addition of Necitumumab to Standard Chemotherapy with Gemcitabine and Cisplatin before Surgery in Squamous Cell Lung Cancer

    This phase II trial investigates how well necitumumab with gemcitabine and cisplatin work before surgery in treating patients with squamous non-small cell lung cancer. Analyzing the tumor cells from many cases of squamous cell lung cancer has shown that this cancer often expresses a special protein called EGFR on the tumor cell. Necitumumab is a type of treatment called a monoclonal antibody that specifically targets EGFR on tumor cells. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving necitumumab, gemcitabine, and cisplatin before surgery may make the tumor smaller. The goal of this trial is to explore whether it is possible to add necitumumab to standard treatment for patients with squamous cell lung cancer that can be surgically removed.
    Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York

  • CCR2 / CCR5 Antagonist BMS-813160, Nivolumab, Gemcitabine Hydrochloride, and Nab-Paclitaxel in Treating Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer

    This phase I / II trial studies the side effects of CCR2 / CCR5 antagonist BMS-813160, nivolumab, gemcitabine hydrochloride, and nab-paclitaxel and how well they work in treating patients with pancreatic cancer that can be borderline removed by surgery (resectable) or has spread to nearby tissue or lymph nodes (locally advanced). Immunotherapy with CCR2 / CCR5 antagonist BMS-813160, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as gemcitabine hydrochloride and nab-paclitaxel, may work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving CCR2 / CCR5 antagonist BMS-813160, nivolumab, gemcitabine hydrochloride, and nab-paclitaxel may work better in treating patients with pancreatic cancer.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

    This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting. Participants in the experimental arm will receive alectinib at 600 mg orally twice daily (BID) taken with food for 24 months. Participants in the control arm will receive one of the protocol specified platinum based chemotherapy regimens for 4 cycles. Following treatment completion, participants will be followed up for their disease until disease recurrence. At the time of disease recurrence, participants will enter a survival follow-up until death, withdrawal of consent or study closure, whichever occurs earlier.
    Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts

  • Ribociclib, Gemcitabine Hydrochloride, Trametinib, and Sonidegib in Treating Patients with Refractory or Recurrent Brain Cancers

    This phase I trial studies the best dose and side effects of ribociclib, gemcitabine hydrochloride, trametinib, and sonidegib in treating children and young adults with brain cancers that have come back (recurrent) or do not respond to treatment (refractory). Ribociclib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and sonidegib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ribociclib, gemcitabine hydrochloride, trametinib, and sonidegib may work better at treating brain cancers.
    Location: Saint Jude Children's Research Hospital, Memphis, Tennessee

  • Gemcitabine Hydrochloride, Nab-Paclitaxel, and Hydroxychloroquine Sulfate with or without Avelumab in Treating Participants with Resectable Pancreatic Cancer Before Surgery

    This phase II trial studies how well gemcitabine hydrochloride, nab-paclitaxel, and hydroxychloroquine sulfate with or without avelumab work before surgery in treating participants with pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, nab-paclitaxel, and hydroxychloroquine sulfate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as avelumab, may interfere with the ability of tumor cells to grow and spread. Giving gemcitabine hydrochloride, nab-paclitaxel, hydroxychloroquine sulfate and avelumab before surgery may work better in treating participants with pancreatic cancer.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Gemcitabine and Nab-Paclitaxel with or without Pharmacological Ascorbate in Treating Patients with Metastatic Pancreatic Cancer

    This phase II trial studies how well gemcitabine and nab-paclitaxel with or without pharmacological ascorbate works in treating patients with pancreatic cancer that has spread to other places in the body. Pharmacological ascorbate may change the effectiveness of chemotherapy. Drugs used in chemotherapy, such as gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known how pharmacological ascorbate will affect the effectiveness of chemotherapy.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • Nintedanib Alone followed by Nintedanib, Gemcitabine Hydrochloride, and Nab-paclitaxel in Treating Participants with Locally Advanced or Metastatic Pancreatic Adenocarcinoma

    This phase 1b / II trial studies the side effects of nintedanib alone followed by nintedanib, gemcitabine hydrochloride, and nab-paclitaxel in treating participants who have pancreatic adenocarcinoma that has spread to nearby tissue or lymph nodes, or has spread to other places in the body. Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nintedanib in combination with gemcitabine hydrochloride and nab-paclitaxel may kill more tumor cells in participants with advanced pancreatic adenocarcinoma.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • Nab-Paclitaxel and Gemcitabine Hydrochloride in Treating Patients with Relapsed or Progressive Small Cell Cancer after First-Line Therapy

    This phase II trial studies how well nab-paclitaxel and gemcitabine hydrochloride work in treating patients with small cell cancer that has come back or is growing, spreading, or getting worse after first-line therapy. Drugs used in chemotherapy, such as nab-paclitaxel and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

    The purpose of this study is to see if LOAd703 (an oncolytic adenovirus) can be safely given to patients with pancreatic cancer. The study will also evaluate whether or not intratumoral injection of LOAd703 will support current standard of care treatment to reduce the size of the tumor and improve survival of the patients. Adenoviruses are known as the "common cold" virus and most individuals have had multiple infections during their lifetime. Oncolytic adenoviruses are adenoviruses that are modified so they cannot multiply and spread (known as replicating) properly in normal (e.g. healthy) cells, but instead, they infect and replicate very well in cancer cells. This strong replication leads to the death of the cancer cell. Oncolytic viruses have been evaluated in multiple clinical trials for cancer treatment during the past decade and been proven safe. It is common to have a fever the first day or two after virus injection since the immune system will react to the virus infection. The immune system can also kill cancer cells but to do so it needs to be properly stimulated. Oncolytic viruses alone do not seem to be strong enough to activate clinically relevant anti-cancer responses. However, it is thought that if additional immune system stimulators are added to the oncolytic viruses they may be able to result in clinical relevant antic-cancer responses. LOAd703 is an oncolytic adenovirus that has been modified to include additional immune system stimulators. Specifically, genes that stimulate the immune system have been added to the oncolytic adenovirus. Once the oncolytic adenovirus infects the cancer cells, the genes will be expressed, resulting in activation of the immune response so it can attack and kill cancer cells. In this study, LOAd703 will be given by intratumoral injections. It will be given in addition to standard of care treatment with gemcitabine and nab-paclitaxel + / - the anti-PD-L1 antibody atezolizumab. Because this is an experimental therapy, there will be extra visits for disease monitoring and samples accordingly to the detailed information below. The LOAd703 is an investigational agent not approved by the FDA.
    Location: Baylor College of Medicine / Dan L Duncan Comprehensive Cancer Center, Houston, Texas

  • Disulfiram and Chemotherapy in Treating Patients with Refractory Solid Tumors or Metastatic Pancreatic Cancer

    This partially randomized phase I trial studies the side effects and best dose of disulfiram when given together with chemotherapy in treating patients with a solid tumor that does not respond to treatment (refractory) or pancreatic cancer that has spread to other places in the body (metastatic) and to compare whether disulfiram and chemotherapy may reduce tumor induced muscle loss. Weight loss occurs in pancreatic cancer patients and is common in a multitude of other cancers. Patients with metastatic cancer and weight loss sometimes are not able to receive treatment due to physical weakness or debility. Disulfiram is a potential inhibitor of muscle degradation and may reduce tumor induced muscle wasting. Disulfiram may also help chemotherapy work better by making tumor cells more sensitive to the drug. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving chemotherapy with or without disulfiram is a better treatment for refractory solid tumors or metastatic pancreatic cancer.
    Location: Mayo Clinic in Rochester, Rochester, Minnesota

  • Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

    This phase II trial studies how well cisplatin, methotrexate, and gemcitabine hydrochloride given via transarterial perfusion work in treating patients with malignant pleural mesothelioma that cannot be removed by surgery. Drugs used in chemotherapy, such as cisplatin, methotrexate, and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Transarterial chemoperfusion is a procedure that allows chemotherapy agents, such as cisplatin, methotrexate and gemcitabine hydrochloride, to be directly injected into the arteries that supply blood to the area where the tumor is located. Transarterial chemoperfusion with cisplatin, methotrexate, and gemcitabine hydrochloride may be an effective treatment for malignant pleural mesothelioma.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Gemcitabine Hydrochloride, Cisplatin, and Yttrium Y 90-TARE in Treating Patients with Liver Cancer That Cannot Be Removed by Surgery

    This trial studies the side effects and best dose of Yttrium Y 90-transarterial radioembolization (TARE) when given together with gemcitabine hydrochloride and cisplatin in treating patients with liver cancer that cannot be removed by surgery. Transarterial radioembolization uses radioactive drugs, such as Yttrium Y 90 resin microspheres, to kill tumor cells by carrying radiation directly to tumor cells without harming normal cells. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving Yttrium Y 90-transarterial radioembolization together with gemcitabine hydrochloride and cisplatin may kill more tumor cells.
    Location: Medical University of South Carolina, Charleston, South Carolina

  • Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan before Stem Cell Transplant in Treating Patients with Refractory or Relapsed Multiple Myeloma

    This phase II trial studies how well panobinostat, gemcitabine hydrochloride, busulfan, and melphalan before stem cell transplant work in treating patients with multiple myeloma that does not respond to treatment (refractory) or has returned (relapsed). Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving high-dose chemotherapy, such as gemcitabine hydrochloride, busulfan, and melphalan, before a peripheral blood stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient’s bone marrow for new blood-forming cells (stem cells) to grow. Previously collected stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Neoadjuvant GMCI Plus Chemoradiation for Advanced Non-Metastatic Pancreatic Adenocarcinoma

    The purpose of this study is to evaluate Gene Mediated Cytotoxic Immunotherapy (GMCI™) in combination with standard of care chemoradiation and surgery for borderline resectable and unresectable locally advanced pancreatic cancer in patients who have completed induction chemotherapy. GMCI kills tumor cells and creates an immune stimulatory environment in the tumor. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. GMCI has shown synergy with radiation and surgery without added toxicity. The hypothesis is that GMCI added to standard of care chemoradiation and surgery after completion of induction chemotherapy will be safe and will improve the clinical outcome for patients with pancreatic cancer.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Gemcitabine Hydrochloride, Nab-paclitaxel, and Hypofractionated, Image-Guided, Intensity Modulated Radiation Therapy before Surgery in Treating Patients with Newly Diagnosed Pancreatic Cancer That Can Be Removed by Surgery

    This phase II trial studies neoadjuvant therapy (treatment given as a first step to shrink a tumor before the main treatment) comprising gemcitabine hydrochloride, nab-paclitaxel, and hypofractionated, image-guided, intensity modulated radiation therapy (HIGRT) before surgery in treating patients with newly diagnosed pancreatic cancer that can potentially be removed by surgery. Giving gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, and HIGRT before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. HIGRT delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving neoadjuvant gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation together with HIGRT may be a better treatment for pancreatic cancer.
    Location: Duke University Medical Center, Durham, North Carolina

  • Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride in Treating Patients with Stage IV or Recurrent Non-small Cell Lung Cancer

    This phase II trial studies how well paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride work in treating patients with non-small cell lung cancer that is stage IV or has come back (recurrent). Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Radiation Therapy and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Pancreatic Cancer

    This phase I trial studies the side effects and best dose of radiation therapy and paclitaxel albumin-stabilized nanoparticle formulation when given together in treating patients with pancreatic cancer. Radiation therapy uses high energy x-rays and / or protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving radiation therapy and paclitaxel albumin-stabilized nanoparticle formulation before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients with Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

    This phase I / II trial studies the side effects and best dose of vorinostat when given together with gemcitabine hydrochloride and docetaxel and to see how well they work in treating patients with soft tissue sarcoma that has spread to other places in the body (metastatic) or cannot be removed by surgery. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vorinostat with combination chemotherapy may kill more tumor cells than giving either one alone.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Gemcitabine Hydrochloride, Clofarabine, and Busulfan before Donor Stem Cell Transplant in Treating Patients with Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

    This phase I / II trial studies the side effects and best dose of gemcitabine hydrochloride, clofarabine, and busulfan before donor stem cell transplant and to see how well it works in treating patients with B-cell or T-cell non-Hodgkin lymphoma or Hodgkin lymphoma that does not respond to treatment. Giving chemotherapy before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
    Location: M D Anderson Cancer Center, Houston, Texas

  • An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

    The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and / or overall survival compared with chemotherapy in patients with advanced lung cancer.
    Location: University of California San Diego, San Diego, California

  • Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

    This study considers the safety and tolerability of increasing doses of CX-4945 in combination with gemcitabine plus cisplatin to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D), followed by a randomized study that compares antitumor activity in cholangiocarcinoma patients receiving the standard of care gemcitabine plus cisplatin versus CX-4945 at the combination RP2D with gemcitabine plus cisplatin.
    Location: 4 locations

  • Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

    Patients with relapsed or refractory Hodgkin Lymphoma who are CD30+ will receive a standard of care reduced intensity regimen and an allogeneic stem cell transplant (from another person, related or unrelated). Following recovery, patients will receive a medication called Brentuximab Vendotin which is targeted against CD30+ cells. The study hypothesis is that this treatment will be safe and well tolerated in children and young adults.
    Location: Roswell Park Cancer Institute, Buffalo, New York